Review
Biochemistry & Molecular Biology
Na Young Lee, Ki Tae Suk
Summary: Liver cirrhosis is a common chronic liver disease worldwide with various causes, and there is still no clear consensus on its treatment. Recent studies have shown that modulating the gut microbiome with probiotics can ameliorate the progression of liver disease, indicating a potential new treatment approach for cirrhosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Chemistry, Medicinal
Yahong Shi, Tun Yan, Xi Lu, Kai Li, Yifeng Nie, Chuqiao Jiao, Huizhen Sun, Tingting Li, Xiang Li, Dong Han
Summary: Liver fibrosis is a pressing public health issue, and phloridzin has been found to effectively treat liver fibrosis, potentially through mechanisms involving cell ferroptosis, carbon metabolism, and related biomechanical changes.
Review
Microbiology
Nicholas Shalaby, Dorit Samocha-Bonet, Nadeem O. Kaakoush, Mark Danta
Summary: Liver disease is a major global health problem causing millions of deaths each year. Currently, there are no specific registered antifibrotic therapies to reverse liver injury. However, the interaction between the liver and the gastrointestinal microbiome has the potential to offer a novel therapeutic approach to mitigate the progression of liver disease and its complications.
Article
Medicine, Research & Experimental
Yang Liu, Paul M. Cavallaro, Byeong-Moo Kim, Tao Liu, Hongyan Wang, Florian Kuehn, Fatemeh Adiliaghdam, Enyu Liu, Robin Vasan, Ehsan Samarbafzadeh, Matthew Z. Farber, Junhui Li, Meng Xu, Vidisha Mohad, Michael Choi, Richard A. Hodin
Summary: Liver fibrosis is associated with gut barrier dysfunction, and IAP has been identified as a potential therapy to prevent liver fibrosis. Oral IAP supplementation can protect the gut barrier and prevent liver fibrosis via a TLR4-mediated mechanism.
Review
Biochemistry & Molecular Biology
Eleonora Binatti, Alessio Gerussi, Donatella Barisani, Pietro Invernizzi
Summary: This review summarizes the role and functions of macrophages in fibrotic diseases, with a specific focus on liver fibrosis, and discusses innovative therapeutic strategies targeting macrophages in fibrotic liver diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Microbiology
Courtney E. Price, Thomas H. Hampton, Rebecca A. Valls, Kaitlyn E. Barrack, George A. O'Toole, Juliette C. Madan, Modupe O. Coker
Summary: This study describes the longitudinal development of the gut microbiome in children with cystic fibrosis (CF) from birth through early childhood. The results show that the diversity of the gut microbiome increases with age, but plateaus at around 2 years of age for the CF cohort. Certain bacteria associated with dysbiosis in CF change with age towards a healthier composition, while others persist. Additionally, bacteria associated with CF lung disease were found to persist early in life and may contribute to gut microbiota composition.
Review
Nutrition & Dietetics
Paulina Trzeciak, Mariola Herbet
Summary: The intestinal microbiota plays a vital role in the pathophysiology of depression, affecting functions like the gut-brain axis and neurotransmitter synthesis. Deficiencies in vitamins sourced from intestinal bacteria may impact responses to antidepressant therapy and worsen depressive symptoms.
Article
Pediatrics
Mariaelena Filippelli, Roberto Dell'Omo, Angela Amoruso, Ilaria Paiano, Marco Pane, Pasquale Napolitano, Silvia Bartollino, Ciro Costagliola
Summary: This study showed that specific probiotics can alter the clinical course of chalaziosis in children, reducing the time required for complete resolution of the chalazion in a safe and effective manner.
EUROPEAN JOURNAL OF PEDIATRICS
(2021)
Review
Gastroenterology & Hepatology
Lingxuan An, Ulrich Wirth, Dominik Koch, Malte Schirren, Moritz Drefs, Dionysios Koliogiannis, Hanno Niess, Joachim Andrassy, Markus Guba, Alexandr Bazhin, Jens Werner, Florian Kuehn
Summary: Hepatosteatosis is the earliest stage in the pathogenesis of nonalcoholic fatty liver disease and alcoholic liver disease, strongly linked with obesity. Gut dysbiosis and gut barrier dysfunction crucially contribute to the development of chronic liver disease. Treatments targeting the gut microbiome and gut barrier have shown potential benefits in attenuating liver inflammation.
JOURNAL OF GASTROINTESTINAL SURGERY
(2022)
Review
Biochemistry & Molecular Biology
Paschalis Ntolios, Vassilios Tzilas, Evangelos Bouros, Eleni Avdoula, Ioannis Karakasiliotis, Demosthenes Bouros, Paschalis Steiropoulos
Summary: The interest in the lung microbiome and virome and their contribution to the pathogenesis of idiopathic pulmonary fibrosis (IPF) has been increasing. Higher microbial burden is associated with worse prognosis but no specific microbe has been identified to contribute to this. Infection is considered a cause of acute exacerbation of IPF, but the association of viral infection with AE-IPF has not been established.
Review
Biochemistry & Molecular Biology
Nienke Koopman, Drosos Katsavelis, Anne S. ten Hove, Stanley Brul, Wouter J. de Jonge, Jurgen Seppen
Summary: This article discusses the production, secretion, and signaling of the monoamine serotonin (5-HT) in the intestine, as well as its effects on intestinal homeostasis and the immune system.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Immunology
Yan Chen, Fa-Hong Wu, Peng-Qiang Wu, Hong-Yun Xing, Tao Ma
Summary: Commensal bacteria and other microorganisms in the human body play a significant role in the development and treatment of cancers. The tumor microbiome (TM) has been identified in different types of cancers, and it has diverse compositions and effects on tumors. TM is involved in the formation of tumor microenvironment, regulation of local immunity, and modification of tumor cell biology, which directly affects the efficacy of tumor drug treatments. TM has the potential to serve as a biomarker for tumors, and engineered tumor-targeting bacteria and anti-cancer microbial agents are promising in tumor treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Katarzyna Logon, Gabriela Swirkosz, Monika Nowak, Martyna Wrzesniewska, Aleksandra Szczygiel, Krzysztof Gomulka
Summary: The role of the microbiome in asthma pathology and treatment is significant, as highlighted in this article. The interplay between asthma and the microbiome is complex, and further research is needed to clarify the factors that moderate this relationship. The pre-treatment bronchial microbiome in asthmatic patients influences their response to treatment. The gut microbiota and its dysbiosis can contribute to immune system modulation and the development of asthma. An appropriate gut microbiome and its intestinal metabolites are protective factors for asthma development. Prebiotics and specific dietary strategies may have prophylactic or therapeutic effects, but further research is needed for definitive conclusions. While evidence regarding probiotics is inconclusive, recent studies have shown promising effects. Future studies should focus on investigating specific strains and examining their mechanisms and genetic aspects.
Review
Medicine, Research & Experimental
Hourieh Sadrekarimi, Zhanna R. Gardanova, Morteza Bakhshesh, Farnoosh Ebrahimzadeh, Amirhossein Fakhre Yaseri, Lakshmi Thangavelu, Zahra Hasanpoor, Firoozeh Abolhasani Zadeh, Mohammad Saeed Kahrizi
Summary: In recent years, there has been increased focus on the impact of microbial populations in the gastrointestinal tract on human health and diseases, including cancer. Any alteration in the composition and diversity of the gut microflora has been linked to various pathologies, and the microflora may contribute to tumor initiation and progression through chronic inflammation, toxin production, and metabolite generation. Therefore, identifying the bacterial species involved and their mechanisms of action is crucial for preventing and controlling tumors. Additionally, the microbiome plays a role in the therapeutic potential and adverse effects of anti-cancer approaches, highlighting the importance of personalized medicine.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Health Care Sciences & Services
Xiubin Liang, Mohamad Bouhamdan, Xia Hou, Kezhong Zhang, Jun Song, Ke Hao, Jian-Ping Jin, Zhongyang Zhang, Jie Xu
Summary: The study identified a new CF animal model that exhibits intestinal dysbiosis phenotype, which may facilitate research and development of novel treatments for CF-associated gastrointestinal diseases. The fecal microbiomes of CF rabbits showed lower richness and diversity compared to wild-type rabbits, indicating significant taxonomic and functional dysbiosis.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Ruochan Chen, Shan Zhu, Xue-Gong Fan, Haichao Wang, Michael T. Lotze, Herbert J. Zeh, Timothy R. Billiar, Rui Kang, Daolin Tang
Review
Biochemistry & Molecular Biology
Rui Kang, Ruochan Chen, Qiuhong Zhang, Wen Hou, Sha Wu, Lizhi Cao, Jin Huang, Yan Yu, Xue-gong Fan, Zhengwen Yan, Xiaofang Sun, Haichao Wang, Qingde Wang, Allan Tsung, Timothy R. Billiar, Herbert J. Zeh, Michael T. Lotze, Daolin Tang
MOLECULAR ASPECTS OF MEDICINE
(2014)
Article
Multidisciplinary Sciences
Panpan Yi, Yuejin Liang, Denley Ming Kee Yuan, Zuliang Jie, Zakari Kwota, Yan Chen, Yingzi Cong, Xuegong Fan, Jiaren Sun
SCIENTIFIC REPORTS
(2017)
Article
Cell Biology
Songman Yu, Ning Li, Zebing Huang, Ruochan Chen, Panpan Yi, Rui Kang, Daolin Tang, Xingwang Hu, Xuegong Fan
CELL DEATH & DISEASE
(2018)
Article
Gastroenterology & Hepatology
Meijuan Chen, Haijun Huang, Pengcheng Zhou, Jiajie Zhang, Yining Dai, Danhong Yang, Xuegong Fan, Hongying Pan
GASTROENTEROLOGY RESEARCH AND PRACTICE
(2019)
Article
Cell Biology
Zhenguo Liu, Yaqun Yu, Zebing Huang, Yi Kong, Xingwang Hu, Wei Xiao, Jun Quan, Xuegong Fan
CELL DEATH & DISEASE
(2019)
Letter
Public, Environmental & Occupational Health
Pengcheng Zhou, Zebing Huang, Yinzong Xiao, Xun Huang, Xue-Gong Fan
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
(2020)
Article
Medicine, General & Internal
Ruochan Chen, Siya Pei, Yayu Chen, Linxia Tan, Ying Xue, Shao Liu, Yan Huang, Xuegong Fan
Summary: This study reported two adult male patients with a suboptimal response to TAF monotherapy, which is an uncommon occurrence. Further long-term observations and extensive data are needed to evaluate the efficacy and safety of TAF, highlighting the importance of developing more robust novel direct-acting antivirals and immune therapies for HBV.
FRONTIERS IN MEDICINE
(2021)